We found that the purified form, B-FAHF-2, significantly suppressed the production of TNF-α by PBMCs and intestinal mucosal from pediatric subjects with CD and abrogated colitis in a murine model at a much lower dose than FAHF-2. The gene discussed is TNF; the disease is colitis.